Edition:
United States

Eagle Pharmaceuticals Inc (EGRX.OQ)

EGRX.OQ on NASDAQ Stock Exchange Global Market

76.01USD
22 Jun 2018
Change (% chg)

$0.36 (+0.48%)
Prev Close
$75.65
Open
$75.60
Day's High
$76.30
Day's Low
$75.00
Volume
310,676
Avg. Vol
97,310
52-wk High
$84.20
52-wk Low
$45.05

Chart for

About

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its... (more)

Overall

Beta: 1.43
Market Cap(Mil.): $1,127.64
Shares Outstanding(Mil.): 14.84
Dividend: --
Yield (%): --

Financials

  EGRX.OQ Industry Sector
P/E (TTM): 34.11 28.95 33.54
EPS (TTM): 2.23 -- --
ROI: 17.09 13.56 13.09
ROE: 20.31 15.37 15.10

BRIEF-Eagle Pharmaceuticals Gets Final FDA Approval For Bendamustine Hydrochloride Ready-To-Dilute Solution In 500Ml Admixture

* EAGLE PHARMACEUTICALS INC GRANTED FINAL FDA APPROVAL FOR BENDAMUSTINE HYDROCHLORIDE READY-TO-DILUTE SOLUTION IN A 500ML ADMIXTURE

May 16 2018

BRIEF-Eagle Pharmaceuticals Reports Q1 Adjusted Non-GAAP Earnings Per Share Of $0.53

* EAGLE PHARMACEUTICALS, INC. REPORTS FIRST QUARTER 2018 RESULTS

May 10 2018

BRIEF-Eagle Pharmaceuticals Says CEO Scott Tarriff's 2017 Total Compensation Was $8.04 Mln

* EAGLE PHARMACEUTICALS INC SAYS CEO SCOTT TARRIFF'S 2017 TOTAL COMPENSATION WAS $8.04 MILLION VERSUS $7.15 MILLION IN 2016 – SEC FILING Source : https://bit.ly/2HK04hV Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 30 2018

BRIEF-Eagle Pharmaceuticals’ Vasopressin ANDA Accepted For Filing By The FDA

* EAGLE PHARMACEUTICALS’ VASOPRESSIN ANDA ACCEPTED FOR FILING BY THE FDA

Apr 16 2018

BRIEF-Eagle Pharmaceuticals - Announced Co's Eagle Biologics Division Has Been Issued A New Patent

* EAGLE PHARMACEUTICALS - ANNOUNCED CO'S EAGLE BIOLOGICS DIVISION HAS BEEN ISSUED A NEW PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 27 2018

BRIEF-Eagle Pharmaceuticals Reports Q4 EPS Of $0.58

* EAGLE PHARMACEUTICALS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS

Feb 26 2018

BRIEF-Iridian Asset Management LLC Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals As Of Dec. 31, 2017 - SEC Filing‍​

* IRIDIAN ASSET MANAGEMENT LLC REPORTS 10.1 PERCENT PASSIVE STAKE IN EAGLE PHARMACEUTICALS INC AS OF DEC. 31, 2017 - SEC FILING‍​ Source text: (http://bit.ly/2En48mt) Further company coverage:

Jan 08 2018

BRIEF-Iridian Asset Management Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals

* IRIDIAN ASSET MANAGEMENT REPORTS 10.1 PERCENT PASSIVE STAKE IN EAGLE PHARMACEUTICALS AS OF DEC 31, 2017 - SEC FILING‍​ Source text: (http://bit.ly/2AG5uGB) Further company coverage:

Jan 08 2018

Earnings vs. Estimates